期刊文献+

从病例分析看银屑病关节炎的诊断和治疗 被引量:1

原文传递
导出
摘要 银屑病关节炎(psoriasis arthritis,PsA)是一种与银屑病相关的炎症性关节病,具有银屑病皮疹和关节炎症表现。我国的患病率约为0.123%,男女比例相近。因为该病患者类风湿因子多为阴性,部分患者可有骶髂关节和(或)脊柱炎,故该病被列入血清阴性脊柱关节病。该病发病机制尚未明确,研究发现与遗传、免疫和环境因子等多种因素有关。下面通过一个PsA病例进一步分析该病的诊治原则。
出处 《中华全科医师杂志》 2006年第7期436-438,418,共4页 Chinese Journal of General Practitioners
  • 相关文献

参考文献8

  • 1何榕,毛节明.胰岛素在动脉粥样硬化和再狭窄发病中的作用[J].心血管病学进展,2005,26(5):491-493. 被引量:3
  • 2Mathews DR, Hosker JP, Rudenski AS, et al. Homesstasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia,1985,28:412-419.
  • 3Ansten WG, Edwards JE, Erye RL, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation,1975,51 (4 Suppl) :5-40.
  • 4Karabulut A, lltumur K, Toprak N , et al. Insulin response to oral glucose loading and coronary artery disease in nondiabetics. Int Heart J, 2005,46:761-770.
  • 5Takezako T, Saku K, Zhang B, et al. Insulin resistance and angiographical characteristics of coronary atherosclerosis. Jpn Cite J,1999,63:666-673.
  • 6Shinozaki K, Hirayama A, Nishio Y, et al. Coronary endothelial dysfunction in the insulin-resistance state is linked to abnormal pteridine metabolism and vascular oxidative stress. J Am Coil Cardiol, 2001,38:1821-1828.
  • 7Shinozaki K, Suzuki M, Ikebuchi M, et al. Insulin resistance associated with compensatory hyperinsulinemia as an independent risk factor for vasospastic angina. Circulation, 1995,92:1749-1757.
  • 8Dagres N, SaUer B, Haude M, et al. Insulin sensitivity and coronary vasoreactivity: insulin sensitivity relates to adenosine-stimulated coronary flow response in human subjects. Clin Endocrinol, 2004,61:724-731.

二级参考文献25

  • 1Indolfi C,Torella D,Cavuto L,et al.Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats[J].Circulation,2001,103(24):2980-2986.
  • 2Osanai H,Kanayama H,Miyazaki Y,et al.Usefulness of enhanced insulin secretion during an oral glucose tolerance test as a predictor of restenosis after direct percutaneous transluminal coronary angioplasty during acute myocardial infarction in patients without diabetes mellitus[J].Am J Cardiol,1998,81(6):698-701.
  • 3Arai T,Wang N,Bezouevski M,et al.Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene[J].J Biol Chem,1999,274(4):2366-2371.
  • 4Nordestgaard BG,Agerholm-Larsen B,Stender S.Effect of exogenous hyperinsulinaemia on atherogenesis in cholesterol-fed rabbits[J].Diabetologia,1997,40(5):512-520.
  • 5Park SH,Marso SP,Zhou ZM,et al.Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus[J].Circulation,2001,104(7):815-819.
  • 6Montagnani M,Golovchenko I,Kim I,et al.Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells[J].J Biol Chem,2002,277(3):1794-1799.
  • 7Jacob A,Molkentin JD,Smolenski A,et al.Insulin inhibits PDGF-directedVSMC migration via NO/cGMP increase of MKP-1 and its inactivation ofMAPKs[J].Am J Physiol Cell Physiol,2002,283(3):C704-C713.
  • 8Aljada A,Saadeh R,Assian E,et al.Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide[J].J Clin Endocrinol Metab,2000,85(7):2572-2575.
  • 9Aljada A,Saadeh R,Ghanim H,et al.Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells[J].J Clin Endocrinol Metab,2001,86(1):450-453.
  • 10Dandona P,Aljada A,Mohanty P,et al.Insulin inhibits intranuclear NFkappaB and stimulates IkappaB in mononuclear cells in obese subjects:evidence for an anti-inflammatory effect[J]?J Clin Endocrinol Metab,2001,86(7):3257-3265.

共引文献2

同被引文献8

  • 1Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curt D ir Autoimmun, 2010,11 : 180-210.
  • 2Antoni CE,Kavanaugh A,Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations ofpsoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum, 2005, 52: 1227-1236.
  • 3Fantuzzi F, Del Giglio M, Gisondi P, et al. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets ,2008,12 : 1085-1096.
  • 4Rioda WT, Adorni G. Infliximab treatment in psoriatic arthritis: our experience. Acta Biomed, 2006,77:95-102.
  • 5Atteno M, Peluso R, Costa L, et al. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriaticarthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol, 2010, 29:399-403.
  • 6Licastro F, Chiappelli M, Ianni M, et al. Tumor necrosis factor- alpha antagonists : differential clinical effects by different biotechnological molecules. Int J Immunopathol Pharmacol, 2009, 22:567-572.
  • 7Mease P. Infliximab (Remicade) in the treatment of psoriatic arthritis. Ther Clin Risk Manag, 2006, 2:389400.
  • 8Kyle S, Chandler D, Griffiths CE, et al. Guideline for anti-TNF- alpha therapy in psoriatic arthritis. Rheumatology (Oxford), 2005, 44:390-397.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部